Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24067355 | 0.83 | MEN1 (0.46) | RAB9ATAAR1IDO1KMT2AESR1 | |
| SCHEMBL29291900 | 0.83 | ACHE (0.45) | TAAR1IDO1KMT2AESR1ESR2 | |
| SCHEMBL9587186 | 0.82 | TAAR1 (0.39) | TAAR1HTR2AHSP90AA1KMT2A | |
| SCHEMBL254340 | 0.77 | CYP2A6 (0.50) | RAB9ANPC1HTR2AIDO1PYCR1 | |
| SCHEMBL6547394 | 0.76 | CYP1A2 (0.46) | TAAR1IDO1KMT2AESR1ESR2 | |
| SCHEMBL6768070 | 0.76 | TAAR1 (0.50) | TAAR1HTR2AHSP90AA1KMT2APYCR1 | |
| SCHEMBL24106999 | 0.75 | BCHE (0.39) | RAB9ATAAR1IDO1ALDH1A1 | |
| Magnesium SCHEMBL31125581 | 0.75 | CYP2A6 (0.47) | RAB9ANPC1HTR2AIDO1PYCR1 | |
| SCHEMBL3970246 | 0.75 | CYP2A6 (0.47) | RAB9ANPC1HTR2AIDO1PYCR1 | |
| SCHEMBL10729588 | 0.75 | IDO1 (0.56) | RAB9ANPC1IDO1KMT2APYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | NLN, GLS, PRNP | RAB9A 882/4885NPC1 1203/4885TAAR1 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.